Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other analysts also recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd. Craig Hallum cut their target price on Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a research note on Monday, April 1st.

Read Our Latest Stock Analysis on Accelerate Diagnostics

Accelerate Diagnostics Stock Performance

NASDAQ:AXDX opened at $0.86 on Friday. The company has a market capitalization of $18.61 million, a price-to-earnings ratio of -0.18 and a beta of 0.52. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $11.90. The stock has a 50-day simple moving average of $0.99 and a 200 day simple moving average of $3.11.

Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) last announced its quarterly earnings results on Thursday, March 28th. The medical research company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.27). The company had revenue of $3.03 million during the quarter, compared to analyst estimates of $3.80 million. On average, equities research analysts forecast that Accelerate Diagnostics will post -2.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Accelerate Diagnostics

Hedge funds have recently modified their holdings of the company. Virtu Financial LLC increased its position in shares of Accelerate Diagnostics by 95.4% during the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 17,461 shares during the period. Bank of Montreal Can acquired a new position in shares of Accelerate Diagnostics during the 1st quarter valued at $27,000. Cubist Systematic Strategies LLC acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter valued at $29,000. Bank of America Corp DE increased its position in shares of Accelerate Diagnostics by 110.7% during the 4th quarter. Bank of America Corp DE now owns 42,395 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 22,273 shares during the period. Finally, UBS Group AG increased its position in shares of Accelerate Diagnostics by 6,250.0% during the 1st quarter. UBS Group AG now owns 50,800 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 50,000 shares during the period. 17.14% of the stock is currently owned by institutional investors and hedge funds.

Accelerate Diagnostics Company Profile

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

See Also

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.